Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 267

1.

Influence of inflammatory cytokine polymorphisms on eradication rates of Helicobacter pylori.

Sugimoto M, Furuta T, Yamaoka Y.

J Gastroenterol Hepatol. 2009 Nov;24(11):1725-32. doi: 10.1111/j.1440-1746.2009.06047.x. Review.

2.

Influences of proinflammatory and anti-inflammatory cytokine polymorphisms on eradication rates of clarithromycin-sensitive strains of Helicobacter pylori by triple therapy.

Sugimoto M, Furuta T, Shirai N, Ikuma M, Hishida A, Ishizaki T.

Clin Pharmacol Ther. 2006 Jul;80(1):41-50. Epub 2006 Jun 8.

PMID:
16815316
3.

Effects of CYP2C19 and MDR1 genotype on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxycillin and clarithromycin.

Oh JH, Dong MS, Choi MG, Yoo HW, Lee SB, Park YI, Chung IS.

J Gastroenterol Hepatol. 2009 Feb;24(2):294-8. doi: 10.1111/j.1440-1746.2008.05605.x. Epub 2008 Sep 24.

PMID:
18823430
4.

Polymorphism of interleukin-1beta affects the eradication rates of Helicobacter pylori by triple therapy.

Furuta T, Shirai N, Xiao F, El-Omar EM, Rabkin CS, Sugimura H, Ishizaki T, Ohashi K.

Clin Gastroenterol Hepatol. 2004 Jan;2(1):22-30.

PMID:
15017629
5.

Effects of CYP2C19, MDR1, and interleukin 1-B gene variants on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxicillin, and metronidazole.

Gawrońska-Szklarz B, Siuda A, Kurzawski M, Bielicki D, Marlicz W, Droździk M.

Eur J Clin Pharmacol. 2010 Jul;66(7):681-7. doi: 10.1007/s00228-010-0818-1. Epub 2010 Apr 8.

PMID:
20376628
6.

Clarithromycin resistance, tumor necrosis factor alpha gene polymorphism and mucosal inflammation affect H. pylori eradication success.

Zambon CF, Fasolo M, Basso D, D'Odorico A, Stranges A, Navaglia F, Fogar P, Greco E, Schiavon S, Padoan A, Fadi E, Sturniolo GC, Plebani M, Pedrazzoli S.

J Gastrointest Surg. 2007 Nov;11(11):1506-14; discussion 1514. Epub 2007 Sep 11.

PMID:
17846855
7.
8.

Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection.

Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Inaba T, Yamamoto K, Okada H, Yokota K, Oguma K, Shiratori Y.

Am J Gastroenterol. 2003 Nov;98(11):2403-8.

PMID:
14638340
9.

CYP2C19 polymorphism influences Helicobacter pylori eradication.

Kuo CH, Lu CY, Shih HY, Liu CJ, Wu MC, Hu HM, Hsu WH, Yu FJ, Wu DC, Kuo FC.

World J Gastroenterol. 2014 Nov 21;20(43):16029-36. doi: 10.3748/wjg.v20.i43.16029. Review.

10.

Association of inflammatory cytokine gene polymorphisms with platelet recovery in idiopathic thrombocytopenic purpura patients after the eradication of Helicobacter pylori.

Suzuki T, Matsushima M, Shirakura K, Koike J, Masui A, Takagi A, Shirasugi Y, Ogawa Y, Shirai T, Mine T.

Digestion. 2008;77(2):73-8. doi: 10.1159/000121392. Epub 2008 Mar 20.

PMID:
18354254
12.

Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication.

Yang JC, Wang HL, Chern HD, Shun CT, Lin BR, Lin CJ, Wang TH.

Pharmacotherapy. 2011 Mar;31(3):227-38. doi: 10.1592/phco.31.3.227.

PMID:
21361732
13.

Relationship of interleukin-1B gene promoter region polymorphism with Helicobacter pylori infection and gastritis.

Ramis IB, Vianna JS, Halicki PC, Lara C, Tadiotto TF, da Silva Maciel JB, Gonçalves CV, von Groll A, Dellagostin OA, da Silva PE.

J Infect Dev Ctries. 2015 Sep 29;9(10):1108-16. doi: 10.3855/jidc.6123.

14.

Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype.

Sugimoto M, Furuta T.

World J Gastroenterol. 2014 Jun 7;20(21):6400-11. doi: 10.3748/wjg.v20.i21.6400. Review.

15.
16.

IL-1beta and IL-8, matrix metalloproteinase 3, and pepsinogen secretion before and after H. pylori eradication in gastroduodenal phenotypes.

Chang YW, Oh HC, Jang JY, Hwangbo Y, Lee JW, Lee HJ, Joo KR, Dong SH, Kim SS, Kim HJ, Kim BH, Chang R.

Scand J Gastroenterol. 2008;43(10):1184-93. doi: 10.1080/00365520802130209.

PMID:
18609140
17.

Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.

Zhao F, Wang J, Yang Y, Wang X, Shi R, Xu Z, Huang Z, Zhang G.

Helicobacter. 2008 Dec;13(6):532-41. doi: 10.1111/j.1523-5378.2008.00643.x.

PMID:
19166419
18.

First-line eradication for Helicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype.

Saito Y, Serizawa H, Kato Y, Nakano M, Nakamura M, Saito H, Suzuki H, Kanai T.

World J Gastroenterol. 2015 Dec 28;21(48):13548-54. doi: 10.3748/wjg.v21.i48.13548.

19.

Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection.

Furuta T, Sagehashi Y, Shirai N, Sugimoto M, Nakamura A, Kodaira M, Kenmotsu K, Nagano M, Egashira T, Ueda K, Yoneyama M, Ohashi K, Ishizaki T, Hishida A.

Clin Gastroenterol Hepatol. 2005 Jun;3(6):564-73.

PMID:
15952098
20.

Effect of bacterial and host factors on Helicobacter pylori eradication therapy.

Uotani T, Miftahussurur M, Yamaoka Y.

Expert Opin Ther Targets. 2015;19(12):1637-50. doi: 10.1517/14728222.2015.1073261. Epub 2015 Aug 6. Review.

Supplemental Content

Support Center